AstraZeneca’s AZD9056 Shows Promise in Phase IIa Study on Moderate to Severe Crohn’s Disease

AstraZeneca’s AZD9056 Shows Promise in Phase IIa Study on Moderate to Severe Crohn’s Disease
According to a recently published study, AstraZeneca’s AZD9056 – an orally-available purinergic receptor P2X7 antagonist, may be effective in symptom improvement in patients with moderate to severe Crohn’s disease. The study is titled, “Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn’s Disease: A Randomized

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *